MPCA
ABBV icon

Madison Park Capital Advisors’s AbbVie ABBV Stock Holding History

Madison Park Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,192
Closed -$235K – 60
2024
Q3 		$235K Buy
1,192
+7
+0.6% +$1.31K 0.18% 62
2024
Q2 		$203K Buy
1,185
+5
+0.4% +$828 0.17% 67
2024
Q1 		$215K Buy
+1,180
New +$203K 0.19% 61

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Madison Park Capital Advisors's ABBV Position: Q4 2024 in Review

Madison Park Capital Advisors sold out of AbbVie (ABBV) in Q4 2024, closing a stake of 1,192 shares — an estimated $235K sold.

Madison Park Capital Advisors first reported a position in ABBV in Q1 2024 and held it in 3 quarters. The position peaked at $235K in Q3 2024. 3,744 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

  • Madison Park Capital Advisors reported no remaining AbbVie position as of Q4 2024 after selling out during the quarter.
  • Madison Park Capital Advisors sold 1,192 AbbVie shares in Q4 2024, an estimated $235K.
  • Madison Park Capital Advisors first reported a position in AbbVie in Q1 2024 and held it in 3 quarters.
  • Madison Park Capital Advisors's AbbVie position peaked at $235K in Q3 2024.
  • 3,744 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Madison Park Capital Advisors's 13F filing for Q4 2024, filed 17 Jan 2025.